| EMA number | EMEA/H/C/000143 |
| ATC code | A10AB04 |
| Authorisation | 7 May 1997 |
| Withdrawn | 19 February 2001 |
| Revision | - |
For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.
HUMALOG KWIKPEN — ELI LILLY AND CO, approved 2025-05-07 (BLA205747).
108,060 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.